Omaveloxolone Ophthalmic Suspension 1.0% + Omaveloxolone Opthalmic Suspension 0.5% + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Inflammation and Pain Following Ocular Surgery
Conditions
Inflammation and Pain Following Ocular Surgery
Trial Timeline
Feb 28, 2014 → Sep 30, 2014
NCT ID
NCT02065375About Omaveloxolone Ophthalmic Suspension 1.0% + Omaveloxolone Opthalmic Suspension 0.5% + Placebo
Omaveloxolone Ophthalmic Suspension 1.0% + Omaveloxolone Opthalmic Suspension 0.5% + Placebo is a phase 2 stage product being developed by AbbVie for Inflammation and Pain Following Ocular Surgery. The current trial status is completed. This product is registered under clinical trial identifier NCT02065375. Target conditions include Inflammation and Pain Following Ocular Surgery.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02065375 | Phase 2 | Completed |
Competing Products
20 competing products in Inflammation and Pain Following Ocular Surgery
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ISV-305 | Sun Pharmaceutical | Phase 3 | 77 |
| ISV-303 + ISV-303 + DuraSite Vehicle + Xibrom™ | Sun Pharmaceutical | Phase 1/2 | 41 |
| ISV-303 | Sun Pharmaceutical | Phase 3 | 77 |
| ISV-305 | Sun Pharmaceutical | Phase 3 | 77 |
| ISV-303 | Sun Pharmaceutical | Phase 3 | 77 |
| fluticasone propionate + Comparator: Placebo to fluticasone + Comparator: Lipopolysaccharide (LPS) + Comparator: albuterol | Merck | Phase 1 | 33 |
| MAS825 + Placebo | Novartis | Phase 2 | 52 |
| Secukinumab s.c. injection | Novartis | Approved | 85 |
| etanercept | Amgen | Phase 3 | 76 |
| anti-IL-20 + placebo | Novo Nordisk | Phase 1 | 32 |
| NNC0114-0006 + placebo | Novo Nordisk | Phase 2 | 51 |
| NNC0114-0006 + placebo | Novo Nordisk | Phase 1 | 32 |
| NNC0109-0012 + placebo | Novo Nordisk | Phase 2 | 51 |
| NNC 0151-0000-0000 + NNC 0151-0000-0000 + placebo | Novo Nordisk | Phase 1 | 32 |
| catridecacog + placebo | Novo Nordisk | Phase 2 | 51 |
| NNC109-0012 + placebo | Novo Nordisk | Phase 2 | 51 |
| anti-IL-20 + placebo | Novo Nordisk | Phase 1 | 32 |
| NNC0215-0384 + placebo | Novo Nordisk | Phase 1 | 32 |
| NNC 0151-0000-0000 + placebo | Novo Nordisk | Phase 2 | 51 |
| NNC0109-0012 + placebo | Novo Nordisk | Phase 2 | 51 |